{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:31Z","timestamp":1791902671413,"version":"4.3.4"},"reference-count":58,"publisher":"Bioscientifica","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paragangliomas and phaeochromocytomas, recently reclassified to unify the disease as extra-adrenal and intra-adrenal paragangliomas, are rare neuroendocrine tumours. These tumours have an exceptionally strong hereditary component, with up to 40% of cases being driven by germline mutations in susceptibility genes; therefore, a cornerstone of modern PPGL care is the genotype-first approach, which heavily dictates initial assessment, surgical strategy, and follow-up. In recent years, the clinical landscape has evolved rapidly, leading to the publication of more than ten new consensus statements since 2022. This review article highlights some of these major paradigm shifts including i) a transition towards genotype-tailored clinical management, ii) specialized paediatric diagnostic and management protocols, iii) updated histopathological criteria, iv) the use of advanced targeted therapeutics, and v) the integration of novel predictive tools.<\/jats:p>","DOI":"10.1530\/erc-26-0310","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:44:46Z","timestamp":1790855086000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Paraganglioma and phaeochromocytoma: a review of current guidelines and new diagnostic and therapeutic approaches"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9938-8819","authenticated-orcid":true,"given":"Ruth T","family":"Casey","sequence":"first","affiliation":[{"name":"Department of Genomic Medicine, University of Cambridge, Cambridge Biomedical Campus 1 , ,","place":["Cambridge, UK"]},{"name":"Department of Endocrinology, Cambridge University Hospital, Cambridge Biomedical Research Centre, Addenbrooke\u2019s Hospital 2 , ,","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-0106","authenticated-orcid":true,"given":"Charlotte","family":"Lussey-Lepoutre","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Department of Nuclear Medicine, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, APHP 3 , ,","place":["Paris, France"]},{"name":"Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Inserm, Centre de Recherche des Cordeliers 4 , ,","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101309444433000_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"2026101309444433000_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jmedgenet-2018-105714","article-title":"Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma","volume":"56","author":"Ben Aim","year":"2019","journal-title":"J Med Genet"},{"key":"2026101309444433000_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017 13","journal-title":"Cancer Cell"},{"key":"2026101309444433000_bib4","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0373","article-title":"Update on the genetics of paragangliomas","volume":"30","author":"Gimenez-Roqueplo","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026101309444433000_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026101309444433000_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026101309444433000_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Ta\u00efeb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101309444433000_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41574-024-01024-5","article-title":"International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents","volume":"20","author":"Casey","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026101309444433000_bib9","doi-asserted-by":"crossref","first-page":"G113","DOI":"10.1093\/ejendo\/lvaf239","article-title":"European clinical guidance for the management of adrenal and extra-adrenal paraganglioma in children and adolescents: a consensus by the EXPeRT group","volume":"193","author":"Kuhlen","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026101309444433000_bib10","first-page":"3917","article-title":"[Expert consensus on the diagnosis and treatment of metastatic paraganglioma and pheochromocytoma]","volume":"105","author":"Adrenal Group, Chinese Society of Endocrinology","year":"2025","journal-title":"Zhonghua Yixue Zazhi"},{"key":"2026101309444433000_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.eprac.2023.07.027","article-title":"Diagnosis and management of pheochromocytomas and paragangliomas: a guide for the clinician","volume":"29","author":"Sharma","year":"2023","journal-title":"Endocr Pract"},{"key":"2026101309444433000_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ejendo\/lvae113","article-title":"Management and follow-up strategies for patients with head and neck paraganglioma","volume":"191","author":"Richter","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2026101309444433000_bib13","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026101309444433000_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5858\/arpa.2012-0551-OA","article-title":"Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas","volume":"138","author":"Mete","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2026101309444433000_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"key":"2026101309444433000_bib16","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA investigators","volume":"98","author":"Gimenez-Roqueplo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib17","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"key":"2026101309444433000_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2026101309444433000_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J Nucl Med"},{"key":"2026101309444433000_bib20","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib21","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1210\/jc.2011-0333","article-title":"Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy","volume":"96","author":"King","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib22","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","article-title":"Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026101309444433000_bib23","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of nuclear medicine practice guideline\/Society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026101309444433000_bib24","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa039","article-title":"Pheochromocytoma and paraganglioma in children and adolescents: experience of the French Society of pediatric oncology (SFCE)","volume":"4","author":"de Tersant","year":"2020","journal-title":"J Endocr Soc"},{"key":"2026101309444433000_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/archdischild-2023-325419","article-title":"Genotype-phenotype correlations in paediatric and adolescent phaeochromocytoma and paraganglioma: a cross-sectional study","volume":"109","author":"Seabrook","year":"2024","journal-title":"Arch Dis Child"},{"key":"2026101309444433000_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1530\/EC-17-0321","article-title":"Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center","volume":"7","author":"Falhammar","year":"2018","journal-title":"Endocr Connect"},{"key":"2026101309444433000_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/ERC-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2026101309444433000_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.901760","article-title":"Biochemical diagnosis of catecholamine-producing tumors of childhood: neuroblastoma, pheochromocytoma and paraganglioma","volume":"13","author":"Eisenhofer","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026101309444433000_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1651-2227.1992.tb12213.x","article-title":"A single pediatric center experience with 1025 children with hypertension","volume":"81","author":"Wyszy\u0144ska","year":"1992","journal-title":"Acta Paediatr"},{"key":"2026101309444433000_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cen.70025","article-title":"Biochemical diagnosis of phaeochromocytoma and paraganglioma in children and adolescents: a retrospective cohort Study","volume":"103","author":"Potthoff","year":"2025","journal-title":"Clin Endocrinol"},{"key":"2026101309444433000_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2019.03.1620","article-title":"Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: particular importance for early infancy","volume":"494","author":"Peitzsch","year":"2019","journal-title":"Clin Chim Acta"},{"key":"2026101309444433000_bib32","doi-asserted-by":"crossref","first-page":"e4030","DOI":"10.1210\/clinem\/dgaf193","article-title":"Outcomes and therapeutic strategies for head-and-neck paragangliomas associated with succinate dehydrogenase mutations","volume":"110","author":"Devouge","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib33","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/1097-0142(20000615)88:12<2811::AID-CNCR21>3.0.CO;2-7","article-title":"Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal","volume":"88","author":"Jansen","year":"2000","journal-title":"Cancer"},{"key":"2026101309444433000_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026101309444433000_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026101309444433000_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"2026101309444433000_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2026101309444433000_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch Int J Pathol"},{"key":"2026101309444433000_bib39","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41467-025-57595-y","article-title":"Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles","volume":"16","author":"Flynn","year":"2025","journal-title":"Nat Commun"},{"key":"2026101309444433000_bib40","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib41","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib42","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2026101309444433000_bib43","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1210\/clinem\/dgaa441","article-title":"Approach to the patient: perioperative management of the patient with pheochromocytoma or sympathetic paraganglioma","volume":"105","author":"Berends","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib44","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1245\/s10434-015-4519-y","article-title":"Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades","volume":"22","author":"Livingstone","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2026101309444433000_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"key":"2026101309444433000_bib46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"key":"2026101309444433000_bib47","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1200\/JCO-25-00791","article-title":"Phase II study of 177Lu-DOTATATE for progressive metastatic pheochromocytomas and paragangliomas: interim analysis of efficacy, safety, and biomarkers","volume":"43","author":"Lin","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026101309444433000_bib48","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"2026101309444433000_bib49","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"2026101309444433000_bib50","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101309444433000_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","article-title":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","volume":"169","author":"Pamporaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026101309444433000_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1507\/endocrj.EJ25-0165","article-title":"Japan Endocrine Society Clinical Practice Guideline for the diagnosis and management of pheochromocytoma and paraganglioma 2025","volume":"73","author":"Tanabe","year":"2026","journal-title":"Endocr J"},{"key":"2026101309444433000_bib53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgac563","article-title":"Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib54","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1210\/clinem\/dgae797","article-title":"Biomarkers improving genetic and metastatic disease prediction in paraganglioma: insights from a prospective study","volume":"110","author":"Drossart","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101309444433000_bib55","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1541-7786.MCR-20-0992","article-title":"Mastermind like transcriptional coactivator 3 (MAML3) drives neuroendocrine tumor progression","volume":"19","author":"Alzofon","year":"2021","journal-title":"Mol Cancer Res MCR"},{"key":"2026101309444433000_bib56","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s40618-025-02610-8","article-title":"Prognostic markers in pheochromocytomas\/paragangliomas: the role of histopathology, SDHB, MAML3 and MCM6 expression","volume":"48","author":"Yald\u0131r","year":"2025","journal-title":"J Endocrinol Investig"},{"key":"2026101309444433000_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-17-0306","article-title":"TERT structural rearrangements in metastatic pheochromocytomas","volume":"25","author":"Dwight","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026101309444433000_bib58","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0310\/525907\/erc-26-0310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0310\/525907\/erc-26-0310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:45:00Z","timestamp":1791899100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/10\/e260310\/78293\/Paraganglioma-and-phaeochromocytoma-a-review-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0310","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"e260310"}}